// App-Quantinova.ai

EXTH-74 : IND-ENABLING CHARACTERIZATION OF DUAL DRD2- AND ClpP-TARGETING AGENT ONC206 AS THE NEXT IMIPRIDONE FOR CLINICAL NEURO-ONCOLOGY

Researchers

Presenter

  • Varun Prabhu

Principal Investigators

  • Sara Morrow

  • Abed Rahman Kawakibi

  • Yulia Jitkova

  • Jinkyu Jung

  • Neel Madhukar

  • Mathew Garnett

  • Ultan McDermott

  • Cyril Benes

  • Robert Wechsler-Reya

  • Olivier Elemento

  • Sharon DeMorrow

  • Aaron Schimmer

  • Martin Stogniew

  • Brett Theeler

  • Mark Gilbert

  • Joshua Allen

Medical Centers

  • Oncoceutics, Inc., Philadelphia, PA, USA

  • Oncoceutics, Inc., Philadelphia, PA, USA

  • University of Michigan Medical School, Ann Arbor, MI

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • National Cancer Institute, Bethesda, MD

  • Weill Cornell Medicine, New York, NY

  • Sanger Institute, Hinxton, United Kingdom

  • Sanford Burnham Prebys Medical Discovery Institute, Heidelberg, CA

  • Texas A&M College of Medicine, Bryan, TX

  • Princess Margaret Cancer Center, Toronto, ON, Canada

Locations

  • United States

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

  • Solid malignancies

  • Gliomas

Biomarkers

  • N/A

Drug/Treatment

  • Dopamine hydrochloride

  • Casein

  • TIC 10

Outcome

  • N/A

Study Design

  • Open Label

  • Dose Escalation

  • First-In-Human

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved